Antiangiogenic agents in combination with chemotherapy for the treatment of epithelial ovarian cancer

scientific article published on March 2012

Antiangiogenic agents in combination with chemotherapy for the treatment of epithelial ovarian cancer is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1097/IGC.0B013E31823C6EFD
P698PubMed publication ID22266932

P50authorAngeles Alvarez SecordQ87010814
Deanna K TeohQ114338148
P433issue3
P921main subjectchemotherapyQ974135
ovarian cancerQ172341
angiogenesis inhibitorQ574834
P304page(s)348-359
P577publication date2012-03-01
P1433published inInternational Journal of Gynecological CancerQ15749181
P1476titleAntiangiogenic agents in combination with chemotherapy for the treatment of epithelial ovarian cancer
P478volume22

Reverse relations

cites work (P2860)
Q35534413A network model for angiogenesis in ovarian cancer
Q51065459A randomized phase II trial of maintenance therapy with Sorafenib in front-line ovarian carcinoma.
Q37139109Angiogenesis-related pathways in the pathogenesis of ovarian cancer
Q34092176Antiangiogenic Therapy with Human Apolipoprotein(a) Kringle V and Paclitaxel in a Human Ovarian Cancer Mouse Model
Q39239168Anticancer role of MUC1 aptamer-miR-29b chimera in epithelial ovarian carcinoma cells through regulation of PTEN methylation
Q34849516Combination therapy of VEGF-trap and gemcitabine results in improved anti-tumor efficacy in a mouse lung cancer model
Q27023510Contemporary use of bevacizumab in ovarian cancer
Q92524991Differential expression of immune related genes in high-grade ovarian serous carcinoma
Q35829712EGFR is not a major driver for osteosarcoma cell growth in vitro but contributes to starvation and chemotherapy resistance.
Q33460375Effect of indirect nonequilibrium atmospheric pressure plasma on anti-proliferative activity against chronic chemo-resistant ovarian cancer cells in vitro and in vivo.
Q34731353Effects of Treg cells and IDO on human epithelial ovarian cancer cells under hypoxic conditions
Q38757677Efficacy of trebananib (AMG 386) in treating epithelial ovarian cancer
Q37474379Epithelial ovarian cancer-induced angiogenic phenotype of human omental microvascular endothelial cells may occur independently of VEGF signaling
Q34949654In vivo monitoring of angiogenesis inhibition via down-regulation of mir-21 in a VEGFR2-luc murine breast cancer model using bioluminescent imaging
Q38840159Photoacoustic Tomography Detects Early Vessel Regression and Normalization During Ovarian Tumor Response to the Antiangiogenic Therapy Trebananib
Q36103829Prognostic significance of differential expression of angiogenic genes in women with high-grade serous ovarian carcinoma
Q37260459Synthesis of polymer-lipid nanoparticles for image-guided delivery of dual modality therapy
Q38751138The MET/Vascular Endothelial Growth Factor Receptor (VEGFR)-targeted Tyrosine Kinase Inhibitor Also Attenuates FMS-dependent Osteoclast Differentiation and Bone Destruction Induced by Prostate Cancer.
Q37601970The Notch ligand Delta-like 4 (DLL4) as a target in angiogenesis-based cancer therapy?
Q39112597The anti-chemoresistant effect and mechanism of MUC1 aptamer-miR-29b chimera in ovarian cancer
Q41441101VSV based virotherapy in ovarian cancer: the past, the present and …future?

Search more.